Clinical trialNCT00107458CompletedPhase 1Interventional

Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

SponsorChildren's Oncology GroupEnrollment26Brain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol Specific

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in treating patients with recurrent or refractory solid tumors or CNS tumors.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Heidi V. Russell, MD
Texas Children's Cancer Center
Study Chair
clinicaltrials.gov ↗
Jack M. Su, MD
Texas Children's Cancer Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Hospital for Sick Children
Toronto, Ontario, Canada
Hopital Sainte Justine
Montreal, Quebec, Canada

United States

Children'S Hospital of Orange County
Orange, California, United States
Stanford Comprehensive Cancer Center - Stanford
Stanford, California, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Children'S Memorial Hospital - Chicago
Chicago, Illinois, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Dana-Farber/harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Minnesota Children'S Hospital - Fairview
Minneapolis, Minnesota, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, United States
Suny Upstate Medical University Hospital
Syracuse, New York, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Oregon Health & Science University Cancer Institute
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Baylor University Medical Center - Houston
Houston, Texas, United States
Children'S Hospital and Regional Medical Center - Seattle
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Valproate →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2005
Primary completion: 31 Oct 2007
Completion: 31 Mar 2012
Last update posted: 7 Aug 2014
Registered enrollment: 26
Registry id: NCT00107458

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.